{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:39:19Z","timestamp":1790959159000,"version":"4.1.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.beem.2021.101598","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T02:08:23Z","timestamp":1636510103000},"page":"101598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Therapeutic effects of androgens for cachexia"],"prefix":"10.1016","volume":"36","author":[{"given":"Luca","family":"Giovanelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Quinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2021.101598_bib1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/jcsm.12188","article-title":"Comprehensive proteome analysis of human skeletal muscle in cachexia and sarcopenia: a pilot study","volume":"8","author":"Ebhardt","year":"2017","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"key":"10.1016\/j.beem.2021.101598_bib2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/jcsm.12311","article-title":"Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia","volume":"9","author":"Pin","year":"2018","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"key":"10.1016\/j.beem.2021.101598_bib3","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/jcsm.12388","article-title":"Cachexia as a common characteristic in multiple chronic disease","volume":"9","author":"Scherbakov","year":"2018","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"key":"10.1016\/j.beem.2021.101598_bib4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/jcsm.12167","article-title":"Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016","volume":"7","author":"von Haehling","year":"2016","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"key":"10.1016\/j.beem.2021.101598_bib5","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/jcsm.12206","article-title":"Muscle mass and association to quality of life in non-small cell lung cancer patients","volume":"8","author":"Bye","year":"2017","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"key":"10.1016\/j.beem.2021.101598_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jcsm.12127","article-title":"A\u00a0systematic review on the role of vitamins, minerals, proteins, and other supplements for the treatment of cachexia in cancer: a European Palliative Care Research Centre cachexia project","volume":"8","author":"Mochamat","year":"2017","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"key":"10.1016\/j.beem.2021.101598_bib7","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201847258","article-title":"Energy metabolism in cachexia","volume":"20","author":"Rohm","year":"2019","journal-title":"EMBO Rep"},{"key":"10.1016\/j.beem.2021.101598_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jcsm.12238","article-title":"Skeletal muscle performance and ageing","volume":"9","author":"Tieland","year":"2018","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"key":"10.1016\/j.beem.2021.101598_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ageing\/afu115","article-title":"Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS)","volume":"43","author":"Cruz-Jentoft","year":"2014","journal-title":"Age Ageing"},{"key":"10.1016\/j.beem.2021.101598_bib10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.cger.2015.04.005","article-title":"Sarcopenia as the biological substrate of physical frailty","volume":"31","author":"Landi","year":"2015","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.beem.2021.101598_bib11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.clnu.2014.03.007","article-title":"Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia","volume":"33","author":"Biolo","year":"2014","journal-title":"Clin Nutr"},{"key":"10.1016\/j.beem.2021.101598_bib12","first-page":"66","article-title":"Late-onset hypogonadism","volume":"16","author":"Dudek","year":"2017","journal-title":"Przeglad Menopauzalny"},{"key":"10.1016\/j.beem.2021.101598_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/bmjspcare-2020-002601","article-title":"Efficacy and safety of pharmacological cachexia interventions: systematic review and network meta-analysis","volume":"11","author":"Saeteaw","year":"2021","journal-title":"BMJ Support Palliat Care"},{"key":"10.1016\/j.beem.2021.101598_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clnu.2016.07.015","article-title":"ESPEN guidelines on nutrition in cancer patients","volume":"36","author":"Arends","year":"2017","journal-title":"Clin Nutr"},{"key":"10.1016\/j.beem.2021.101598_bib15","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1200\/JCO.20.00611","article-title":"Management of cancer cachexia: ASCO guideline","volume":"38","author":"Roeland","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beem.2021.101598_bib16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/jcsm.12408","article-title":"Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 11th Cachexia Conference","volume":"vol. 10","author":"Ebner","year":"2019","journal-title":"J.\u00a0Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.beem.2021.101598_bib17","first-page":"66","article-title":"Androgenicity\u2013not serum testosterone\u2013correlates best with COVID-19 outcome in European males","author":"Giovanelli","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.beem.2021.101598_bib18","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/978-3-319-99817-6_43","article-title":"Anatomy and physiology of the hypothalamic-pituitary-gonadal (HPG) Axis","author":"Dwyer","year":"2019","journal-title":"Adv. Pract. Endocrinol. Nurs."},{"key":"10.1016\/j.beem.2021.101598_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/17446651.2018.1475227","article-title":"Testosterone, frailty and physical function in older men","volume":"13","author":"Hsu","year":"2018","journal-title":"Expet Rev Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib20","doi-asserted-by":"crossref","first-page":"R99","DOI":"10.1530\/EJE-15-0262","article-title":"Testosterone supplementation and body composition: results from a meta-analysis study","volume":"174","author":"Corona","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2021.101598_bib21","first-page":"3469","article-title":"Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men--a clinical research center study","volume":"81","author":"Brodsky","year":"1996","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib22","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1210\/jc.2006-0357","article-title":"Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men","volume":"91","author":"Sinha-Hikim","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ncpendmet0120","article-title":"Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging","volume":"2","author":"Bhasin","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib24","article-title":"Basal concentrations and acute responses of serum hormones and strength development during heavy resistance training in middle-aged and elderly men and women","volume":"55","author":"H\u00e4kkinen","year":"2000","journal-title":"J\u00a0Geront - Series A Biolog Sci Med Sci"},{"key":"10.1016\/j.beem.2021.101598_bib25","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/jcsm.12472","article-title":"Testosterone therapy induces molecular programming augmenting physiological adaptations to resistance exercise in older men","volume":"10","author":"Gharahdaghi","year":"2019","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"key":"10.1016\/j.beem.2021.101598_bib26","doi-asserted-by":"crossref","first-page":"7399","DOI":"10.1113\/JP272857","article-title":"Synchronous deficits in cumulative muscle protein synthesis and ribosomal biogenesis underlie age-related anabolic resistance to exercise in humans","volume":"594","author":"Brook","year":"2016","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.beem.2021.101598_bib27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamainternmed.2016.9539","article-title":"Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone a controlled clinical trial","volume":"177","author":"Snyder","year":"2017","journal-title":"JAMA Internal Medicine"},{"key":"10.1016\/j.beem.2021.101598_bib28","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1007\/s00198-021-06022-1","article-title":"Effect of testosterone treatment on the trabecular bone score in older men with low serum testosterone","volume":"32","author":"Cauley","year":"2021","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2021.101598_bib29","doi-asserted-by":"crossref","first-page":"e3143","DOI":"10.1210\/clinem\/dgab149","article-title":"Effect of Testosterone treatment on bone microarchitecture and bone mineral density in men: a two-year RCT","volume":"106","author":"Ng Tang Fui","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib30","doi-asserted-by":"crossref","first-page":"E456","DOI":"10.1210\/jc.2010-0902","article-title":"Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy","volume":"95","author":"Hamilton","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib31","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1210\/jc.2013-3233","article-title":"Association between sex steroid levels and bone microarchitecture in men: the STRAMBO study","volume":"99","author":"Argoud","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib32","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/jbmr.3746","article-title":"Relationship between sex steroids and deterioration of bone microarchitecture in older men: the prospective STRAMBO study","volume":"34","author":"Piot","year":"2019","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2021.101598_bib33","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgab181","article-title":"Testosterone therapy effects on bone mass and turnover in hypogonadal men with type 2 diabetes","author":"Colleluori","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib34","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1210\/js.2018-00426","article-title":"Increase in osteocalcin following testosterone therapy in men with type 2 diabetes and subnormal free testosterone","volume":"3","author":"Ghanim","year":"2019","journal-title":"Journal of the Endocrine Society"},{"key":"10.1016\/j.beem.2021.101598_bib35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bone.2017.03.039","article-title":"Hypogonadal men with type 2 diabetes mellitus have smaller bone size and lower bone turnover","volume":"99","author":"Colleluori","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.beem.2021.101598_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00754","article-title":"Androgens and anemia: current trends and future prospects","volume":"10","author":"Al-Sharefi","year":"2019","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2021.101598_bib37","first-page":"648","article-title":"Effect of a single oral dose of oxymetholone on the metabolism of human erythrocytes","volume":"6","author":"Molinari","year":"1978","journal-title":"Exp Hematol"},{"key":"10.1016\/j.beem.2021.101598_bib38","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/BF03345745","article-title":"Androgens and erythropoiesis: past and present","volume":"32","author":"Shahani","year":"2009","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2021.101598_bib39","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1210\/jc.2010-0864","article-title":"Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis","volume":"95","author":"Bachman","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib40","first-page":"776","article-title":"Testosterone administration increases insulin-like growth factor-I levels in normal men","volume":"77","author":"Hobbs","year":"1993","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib41","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/cen.13130","article-title":"Effect of testosterone on hepcidin, ferroportin, ferritin and iron binding capacity in patients with hypogonadotropic hypogonadism and type 2 diabetes","volume":"85","author":"Dhindsa","year":"2016","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2021.101598_bib42","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jamainternmed.2016.9540","article-title":"Association of testosterone levels with anemia in older men a controlled clinical trial","volume":"177","author":"Roy","year":"2017","journal-title":"JAMA Internal Medicine"},{"key":"10.1016\/j.beem.2021.101598_bib43","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1210\/jc.2004-1933","article-title":"Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T","volume":"90","author":"Page","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib44","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1532-5415.2008.01927.x","article-title":"Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men","volume":"56","author":"Storer","year":"2008","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.beem.2021.101598_bib45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2007.51","article-title":"Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial","volume":"299","author":"Emmelot-Vonk","year":"2008","journal-title":"JAMA - Journal of the American Medical Association"},{"key":"10.1016\/j.beem.2021.101598_bib46","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1210\/jc.2009-1251","article-title":"Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study","volume":"95","author":"Srinivas-Shankar","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib47","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/gerona\/glr100","article-title":"Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation","volume":"66 A","author":"Travison","year":"2011","journal-title":"Journals of Gerontology - Series A Biological Sciences and Medical Sciences"},{"key":"10.1016\/j.beem.2021.101598_bib48","first-page":"583","article-title":"Effects of testosterone supplementation for 3 years on muscle performance and physical function in older men","volume":"102","author":"Storer","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib49","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-8587(18)30171-2","article-title":"Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials","volume":"6","author":"Bhasin","year":"2018","journal-title":"The Lancet Diabetes and Endocrinology"},{"key":"10.1016\/j.beem.2021.101598_bib50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/SPC.0000000000000061","article-title":"The assessment and management of cancer cachexia: hypogonadism and hypermetabolism among supportive and palliative care patients","volume":"8","author":"Dev","year":"2014","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.beem.2021.101598_bib51","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1210\/jcem.84.10.6122","article-title":"Selective Androgen Receptor Modulators (SARMs): a novel approach to androgen therapy for the new millennium","volume":"84","author":"Negro-Vilar","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.sxmr.2018.09.006","article-title":"Selective androgen receptor modulators: current knowledge and clinical applications","volume":"7","author":"Solomon","year":"2019","journal-title":"Sexual Medicine Reviews"},{"key":"10.1016\/j.beem.2021.101598_bib53","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.mce.2017.06.013","article-title":"Development of selective androgen receptor modulators (SARMs)","volume":"465","author":"Narayanan","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.beem.2021.101598_bib54","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.21037\/tau.2019.11.02","article-title":"Selective androgen receptor modulators: the future of androgen therapy?","volume":"9","author":"Christiansen","year":"2020","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.beem.2021.101598_bib55","article-title":"Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization","volume":"15","author":"Blanqu\u00e9","year":"2014","journal-title":"BMC Muscoskel Disord"},{"key":"10.1016\/j.beem.2021.101598_bib56","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/bcp.13316","article-title":"Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women","volume":"83","author":"Clark","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.beem.2021.101598_bib57","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/jc.2017-02644","article-title":"GSK2881078, a SARM, produces dose-dependent increases in lean mass in healthy older men and women","volume":"103","author":"Neil","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib58","first-page":"177","article-title":"Selective androgen receptor modulator, S42 has anabolic and anti-catabolic effects on cultured myotubes","volume":"17","author":"Muta","year":"2019","journal-title":"Biochemistry Biophysics Rep"},{"key":"10.1016\/j.beem.2021.101598_bib59","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13539-011-0034-6","article-title":"The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial","volume":"2","author":"Dalton","year":"2011","journal-title":"J\u00a0Cachexia, Sarcopenia and Muscle"},{"key":"10.1016\/j.beem.2021.101598_bib60","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","article-title":"Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial","volume":"14","author":"Dobs","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2021.101598_bib61","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-016-0522-0","article-title":"Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER trials)","volume":"18","author":"Crawford","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.beem.2021.101598_bib62","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1111\/bcp.13345","article-title":"The long and winding road for selective androgen receptor modulators","volume":"83","author":"Dalton","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.beem.2021.101598_bib63","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/SPC.0000000000000381","article-title":"The relationship between muscle mass and function in cancer cachexia: smoke and mirrors?","volume":"12","author":"Ramage","year":"2018","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.beem.2021.101598_bib64","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4103\/1008-682X.122581","article-title":"Androgen effects on skeletal muscle: implications for the development and management of frailty","volume":"16","author":"O'Connell","year":"2014","journal-title":"Asian J Androl"},{"key":"10.1016\/j.beem.2021.101598_bib65","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/cen.12641","article-title":"Male central hypogonadism secondary to exogenous androgens: a review of the drugs and protocols highlighted by the online community of users for prevention and\/or mitigation of adverse effects","volume":"82","author":"Karavolos","year":"2015","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2021.101598_bib66","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1210\/jc.2018-01882","article-title":"Diagnosis and management of anabolic androgenic steroid use","volume":"104","author":"Anawalt","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib67","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1001\/jama.2017.17069","article-title":"Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet","volume":"318","author":"Van Wagoner","year":"2017","journal-title":"JAMA - J Am Med Assoc"},{"key":"10.1016\/j.beem.2021.101598_bib68","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/dta.2512","article-title":"Human in\u00a0vivo metabolism study of LGD-4033","volume":"10","author":"Fragkaki","year":"2018","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.beem.2021.101598_bib69","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/dta.2527","article-title":"Studies on the in\u00a0vivo metabolism of the SARM YK11: identification and characterization of metabolites potentially useful for doping controls","volume":"10","author":"Piper","year":"2018","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.beem.2021.101598_bib70","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-540-79088-4_5","article-title":"Synthetic anabolic agents: steroids and nonsteroidal selective androgen receptor modulators","volume":"195","author":"Thevis","year":"2010","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.beem.2021.101598_bib71","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00126334-200404010-00006","article-title":"Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy","volume":"35","author":"Moyle","year":"2004","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.beem.2021.101598_bib72","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1210\/jc.2004-0451","article-title":"Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial","volume":"89","author":"Esposito","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib73","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1210\/jc.2005-0275","article-title":"A\u00a0randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment","volume":"90","author":"Storer","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib74","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.clinthera.2007.11.004","article-title":"Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment","volume":"29","author":"Gelato","year":"2007","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.beem.2021.101598_bib75","doi-asserted-by":"crossref","first-page":"86","DOI":"10.21037\/apm.2018.08.02","article-title":"Sarcopenia associated with chemotherapy and targeted agents for cancer therapy","volume":"8","author":"Davis","year":"2019","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.beem.2021.101598_bib76","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/14712598.2016.1208168","article-title":"Novel therapeutic options for cachexia and sarcopenia","volume":"16","author":"Molfino","year":"2016","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.beem.2021.101598_bib77","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1470-2045(14)71154-4","article-title":"Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials","volume":"16","author":"Garcia","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2021.101598_bib78","first-page":"3495","article-title":"Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial","volume":"24","author":"Takayama","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.beem.2021.101598_bib79","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2021.101598_bib80","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/cncr.31128","article-title":"Anamorelin (ONO-7643) for the treatment of patients with non\u2013small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)","volume":"124","author":"Katakami","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.beem.2021.101598_bib81","first-page":"1651","article-title":"Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis","volume":"25","author":"Bai","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.beem.2021.101598_bib82","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2017.07.023","article-title":"Anamorelin for advanced non-small-cell lung cancer with cachexia: systematic review and meta-analysis","volume":"112","author":"Nishie","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.beem.2021.101598_bib83","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1161\/01.CIR.0000149746.62908.BB","article-title":"Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure","volume":"110","author":"Nagaya","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2021.101598_bib84","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-5080-4","article-title":"Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials","volume":"18","author":"Advani","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.beem.2021.101598_bib85","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1042\/BCJ20170032","article-title":"Novel targeted therapies for cancer cachexia","volume":"474","author":"Argil\u00e9s","year":"2017","journal-title":"Biochem J"},{"key":"10.1016\/j.beem.2021.101598_bib86","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","article-title":"Treatment of sporadic inclusion body myositis with bimagrumab","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.beem.2021.101598_bib87","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/MCB.01307-13","article-title":"An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy","volume":"34","author":"Lach-Trifilieff","year":"2014","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.beem.2021.101598_bib88","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2213-8587(15)00298-3","article-title":"Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial","volume":"3","author":"Becker","year":"2015","journal-title":"The Lancet Diabetes and Endocrinology"},{"key":"10.1016\/j.beem.2021.101598_bib89","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2021.101598_bib90","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.critrevonc.2018.05.006","article-title":"Cancer cachexia: diagnosis, assessment, and treatment","volume":"127","author":"Sadeghi","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.beem.2021.101598_bib91","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/ehf2.12184","article-title":"Cardiac muscle wasting in individuals with cancer cachexia","volume":"4","author":"Barkhudaryan","year":"2017","journal-title":"ESC Heart Failure"},{"key":"10.1016\/j.beem.2021.101598_bib92","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1615\/CritRevOncog.v17.i3.80","article-title":"Multitargeted treatment of cancer cachexia","volume":"17","author":"Madeddu","year":"2012","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.beem.2021.101598_bib93","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.trecan.2018.10.001","article-title":"Cancer cachexia: more than skeletal muscle wasting","volume":"4","author":"Schmidt","year":"2018","journal-title":"Trends in Cancer"},{"key":"10.1016\/j.beem.2021.101598_bib94","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/CCO.0000000000000517","article-title":"Cancer cachexia, a clinical challenge","volume":"31","author":"Argil\u00e9s","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.beem.2021.101598_bib95","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/SPC.0000000000000464","article-title":"Endocrinopathies and cancer cachexia","volume":"13","author":"Dev","year":"2019","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.beem.2021.101598_bib96","first-page":"2599","article-title":"Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial","volume":"21","author":"Del Fabbro","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.beem.2021.101598_bib97","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/jcsm.12295","article-title":"A\u00a0randomized trial of adjunct testosterone for cancer-related muscle loss in men and women","volume":"9","author":"Wright","year":"2018","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"key":"10.1016\/j.beem.2021.101598_bib98","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.9513","article-title":"A\u00a0phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy","volume":"26","author":"Lesser","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beem.2021.101598_bib99","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0140-6736(96)07015-8","article-title":"Wasting as independent risk factor for mortality in chronic heart failure","volume":"349","author":"Anker","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2021.101598_bib100","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/euhj.2001.2783","article-title":"Guidelines for the diagnosis and treatment of chronic heart failure","volume":"22","author":"Remme","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2021.101598_bib101","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2021.101598_bib102","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.beem.2021.101598_bib103","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.hfc.2019.08.006","article-title":"Cardiac cachexia revisited: the role of wasting in heart failure","volume":"16","author":"Valentova","year":"2020","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.beem.2021.101598_bib104","article-title":"Impact of incident heart failure on body composition over time in the Health, Aging, and Body Composition study population","volume":"10","author":"Forman","year":"2017","journal-title":"Circulation: Heart Fail"},{"key":"10.1016\/j.beem.2021.101598_bib105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1017\/S0029665115002438","article-title":"The wasting continuum in heart failure: from sarcopenia to cachexia","volume":"74","author":"Von Haehling","year":"2015","journal-title":"Proc Nutr Soc"},{"key":"10.1016\/j.beem.2021.101598_bib106","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/ejhf.1304","article-title":"Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)","volume":"20","author":"Emami","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.beem.2021.101598_bib107","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijcard.2003.05.050","article-title":"Wasting of the left ventricle in patients with cardiac cachexia: a cardiovascular magnetic resonance study","volume":"97","author":"Florea","year":"2004","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.beem.2021.101598_bib108","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12020-012-9836-3","article-title":"Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status","volume":"43","author":"Christensen","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2021.101598_bib109","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/jcsm.12191","article-title":"Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial","volume":"8","author":"Clark","year":"2017","journal-title":"J\u00a0Cachexia, Sarcopenia Muscle"},{"key":"10.1016\/j.beem.2021.101598_bib110","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s10741-019-09784-3","article-title":"Pharmacological management of cardiac cachexia: a review of potential therapy options","volume":"24","author":"Rolfe","year":"2019","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.beem.2021.101598_bib111","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrcardio.2017.51","article-title":"Muscle wasting and cachexia in heart failure: mechanisms and therapies","volume":"14","author":"Von Haehling","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.beem.2021.101598_bib112","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13539-010-0008-0","article-title":"The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study","volume":"1","author":"Rozentryt","year":"2010","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"key":"10.1016\/j.beem.2021.101598_bib113","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1161\/CIRCULATIONAHA.111.047381","article-title":"Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized leipzig exercise intervention in chronic heart failure and aging catabolism study","volume":"125","author":"Gielen","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2021.101598_bib114","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0195-668X(03)00083-6","article-title":"Acute haemodynamic effects of testosterone in men with chronic heart failure","volume":"24","author":"Pugh","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2021.101598_bib115","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/hrt.2003.014639","article-title":"Testosterone treatment for men with chronic heart failure","volume":"90","author":"Pugh","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.beem.2021.101598_bib116","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/eurheartj\/ehi443","article-title":"Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial","volume":"27","author":"Malkin","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2021.101598_bib117","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2009.04.078","article-title":"Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure. A double-blind, placebo-controlled, randomized study","volume":"54","author":"Caminiti","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.beem.2021.101598_bib118","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jacc.2010.03.090","article-title":"Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study","volume":"56","author":"Iellamo","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.beem.2021.101598_bib119","first-page":"315","article-title":"Testosterone supplementation in heart failure a meta-analysis","volume":"5","author":"Toma","year":"2012","journal-title":"Circulation: Heart Fail"},{"key":"10.1016\/j.beem.2021.101598_bib120","first-page":"1S","article-title":"Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of state and territorial epidemiologists; AIDS program, center for infectious diseases","volume":"36","year":"1987","journal-title":"MMWR Supplements"},{"key":"10.1016\/j.beem.2021.101598_bib121","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2174\/1389450043490505","article-title":"The pharmacological treatment of cachexia","volume":"5","author":"Argiles","year":"2005","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.beem.2021.101598_bib122","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/500398","article-title":"Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort","volume":"42","author":"Mangili","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.beem.2021.101598_bib123","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00126334-200211010-00001","article-title":"Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA Panel","volume":"31","author":"Schambelan","year":"2002","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.beem.2021.101598_bib124","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.00426.2001","article-title":"Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men","volume":"283","author":"Roubenoff","year":"2002","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.beem.2021.101598_bib125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/QAI.0000000000000821","article-title":"Longitudinal changes over 10 Years in free testosterone among HIV-infected and HIV-uninfected men","volume":"71","author":"Slama","year":"2016","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.beem.2021.101598_bib126","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1086\/317457","article-title":"Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy","volume":"31","author":"Rietschel","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.beem.2021.101598_bib127","first-page":"1332","article-title":"Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting 1","volume":"82","author":"Grinspoon","year":"1997","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib128","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S1473-3099(02)00441-3","article-title":"Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis","volume":"2","author":"Kong","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.beem.2021.101598_bib129","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002836.pub2","article-title":"Anabolic steroids for the treatment of weight loss in HIV-infected individuals","volume":"2010","author":"Johns","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.beem.2021.101598_bib130","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/jama.283.6.763","article-title":"Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels","volume":"283","author":"Bhasin","year":"2000","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.beem.2021.101598_bib131","first-page":"60","article-title":"Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men 1","volume":"85","author":"Grinspoon","year":"2000","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib132","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archpsyc.57.2.141","article-title":"A\u00a0double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms","volume":"57","author":"Rabkin","year":"2000","journal-title":"Arch Gen Psychiatr"},{"key":"10.1016\/j.beem.2021.101598_bib133","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an endocrine society","volume":"103","author":"Bhasin","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib134","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00002030-199606001-00008","article-title":"Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection","volume":"10","author":"Gold","year":"1996","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2021.101598_bib135","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1079\/BJN19960116","article-title":"Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection","volume":"75","author":"Hengge","year":"1996","journal-title":"Br J Nutr"},{"key":"10.1016\/j.beem.2021.101598_bib136","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1097\/00002030-199612000-00010","article-title":"Oxandrolone in AIDS-wasting myopathy","volume":"10","author":"Berger","year":"1996","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2021.101598_bib137","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1210\/jc.2002-021827","article-title":"Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment","volume":"88","author":"Crawford","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2021.101598_bib138","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/archinte.1996.00440100065008","article-title":"Testosterone therapy in glucocorticoid-treated men","volume":"156","author":"Reid","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beem.2021.101598_bib139","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1210\/jc.2009-2354","article-title":"Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline","volume":"95","author":"Bhasin","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metabol"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X21001159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X21001159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:57:47Z","timestamp":1761497867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X21001159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":139,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1521690X21001159"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2021.101598","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic effects of androgens for cachexia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2021.101598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101598"}}